Pharmaceuticals, Biotechnology and Life Sciences
Alvotech has raised $300 million through a private bond offering to fuel continued growth, refinance of existing debt and the further development of Alvotech’s biosimilar assets.
Wren Therapeutics has cashed in £18 million from an international syndicate led by The Baupost Group, in a Series A financing round, which also included LifeForce Capital and a number of high net worth individual investors, the company said Tuesday.
Vertex Pharmaceuticals Limitedgot will extend label for its cystic fibrosis children patients treatment Orkambi in Europe, after the Union’s Commissions’ approval.
Taisho Pharmaceutical Holdings has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion, Bristol-Myers Squibb said in a statement on Saturday.
The UK market focused joint venture between Canopy Growth Corporation and Beckley Canopy Therapeutics will exclusively distribute Cannabis medicinal products of newly formed, built-for-purpose distribution company that will introduce Spectrum Cannabis medicinal cannabis products to UK patients and doctors.
Redx got back on track to resume clinical evaluation of RXC004 in patients with advanced solid tumours in the first half of 2019.
Bavarian Nordic said Friday that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has exercised $44 million option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine.
Erytech Pharma today presents poster entitled about A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma, in an event in San Francisco.
AgeneBio has enrolled its first out of 830 patient in a Phase 3 clinical trial of its investigational medication AGB101, to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD).
Announcing the approval of Teva’s Sabril generic tablets, FDA Commissioner, Scott Gottlieb said that prioritizing the approval of generic drugs to compete with medicines that face little or no competition is the Agency’s key part of efforts to support access and reduce drug costs to patients.